Insider Selling: Twist Bioscience (NASDAQ:TWST) CFO Sells $1,521,806.16 in Stock

Posted by Stanley Muller on Oct 8th, 2026

Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) CFO Adam Laponis sold 8,057 shares of Twist Bioscience stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total value of $1,521,806.16. Following the completion of the sale, the chief financial officer directly owned 100,576 shares of the company’s stock, valued at $18,996,794.88. The trade was a 7.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Adam Laponis also recently made the following trade(s):

On Thursday, July 9th, Adam Laponis sold 2,399 shares of Twist Bioscience stock. The shares were sold at an average price of $94.33, for a total value of $226,297.67.

Twist Bioscience Stock Down 6.8%

TWST stock opened at $155.65 on Thursday. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $219.71. The business’s 50-day moving average is $141.74 and its two-hundred day moving average is $95.17. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The company has a market cap of $9.76 billion, a price-to-earnings ratio of -70.11 and a beta of 2.19.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. During the same quarter in the prior year, the firm earned $0.33 earnings per share. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Analysts Set New Price Targets

TWST has been the subject of several recent research reports. BWS Financial restated a “sell” rating and set a $45.00 target price on shares of Twist Bioscience in a research report on Friday, September 18th. Evercore downgraded shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target on the stock. in a research report on Monday, July 6th. Robert W. Baird lifted their price target on shares of Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Guggenheim boosted their price objective on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Finally, TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $126.18.

Get Our Latest Analysis on TWST

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TWST. Allworth Financial LP purchased a new stake in Twist Bioscience in the 2nd quarter worth approximately $62,000. Trifecta Capital Advisors LLC bought a new stake in Twist Bioscience during the 2nd quarter worth approximately $63,000. Western Wealth Management LLC purchased a new position in Twist Bioscience during the first quarter valued at approximately $31,000. Strs Ohio purchased a new position in Twist Bioscience during the first quarter valued at approximately $33,000. Finally, GAMMA Investing LLC lifted its holdings in Twist Bioscience by 24.4% during the second quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after purchasing an additional 185 shares in the last quarter.

Twist Bioscience News Roundup

Here are the key news stories impacting Twist Bioscience this week:

Positive Sentiment: Recent business momentum remains intact: Twist’s latest quarterly update included record revenue of $118.4 million, revenue growth of 23% year over year, gross margin above 52%, and higher full-year revenue guidance. Revenue also exceeded analyst expectations, although the company remained loss-making.
Positive Sentiment: Lilly collaboration initially boosted enthusiasm: News of the Lilly TuneLab partnership helped drive a substantial rally, reflecting investor interest in Twist’s synthetic-DNA platform and potential drug-discovery applications. However, the durability and strategic value of the collaboration are now being debated.
Positive Sentiment: Some analysts remain constructive: Guggenheim reportedly raised its price target to $212 and maintained a buy rating, while broader analyst coverage still reflects a “Moderate Buy” consensus. Twist Bioscience stock gained after Lilly deal
Neutral Sentiment: Insider transactions were largely prearranged: CEO Emily Leproust sold shares under a Rule 10b5-1 plan, including stock used for tax withholding, while other executives also reported sales. These transactions do not necessarily indicate discretionary bearish views, but the concentration of selling has attracted investor attention. SEC insider transaction filing
Negative Sentiment: Insider selling and valuation pressure: Recent filings showed sales by Leproust and other insiders, while reported insider activity over the past six months contained sales but no purchases. With TWST trading far above many older analyst targets and still posting losses, the filings encouraged profit-taking after the stock’s major run-up.
Negative Sentiment: Partnership skepticism and dilution concerns: Analysts questioning the eventual strategic payoff from the Lilly deal weakened the bullish narrative. Investors are also mindful of Twist’s $300 million August stock offering, which increased potential dilution.

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.